BMY Gets EC Nod for Opdivo Plus Yervoy in First-Line Colorectal Cancer

Bristol Myers Squibb (BMY) announced that the European Commission has approved the combination of its blockbuster immuno-oncology drug Opdivo (nivolumab) and Yervoy (ipilimumab) for a new cancer indication.The EC has approved Opdivo plus Yervoy for the first-line treatment of adult patients with microsatellite instability–high (MSI-H) or mismatch repair deficient (dMMR) unresectable or metastatic colorectal cancer (mCRC).Following the latest nod, Opdivo plus Yervoy became the first dual checkpoint inhibitor ...